

Contents

Preface to the First Edition	xv
Preface to the Second Edition	xvii
Acknowledgements	xix
Abbreviations	xxi
1 An introduction to drugs, their action and discovery	1
1.1 Introduction	1
1.2 What are drugs and why do we need new ones?	1
1.3 Drug discovery and design: a historical outline	3
1.3.1 The general stages in modern-day drug discovery and design	7
1.4 Leads and analogues: some desirable properties	9
1.4.1 Bioavailability	9
1.4.2 Solubility	10
1.4.3 Structure	10
1.4.4 Stability	11
1.5 Sources of leads and drugs	14
1.5.1 Ethnopharmaceutical sources	15
1.5.2 Plant sources	15
1.5.3 Marine sources	17
1.5.4 Microorganisms	18
1.5.5 Animal sources	20
1.5.6 Compound collections, data bases and synthesis	20
1.5.7 The pathology of the diseased state	21
1.5.8 Market forces and 'me-too drugs'	21
1.6 Methods and routes of administration: the pharmaceutical phase	21
1.7 Introduction to drug action	24
1.7.1 The pharmacokinetic phase (ADME)	25
1.7.2 The pharmacodynamic phase	32
1.8 Classification of drugs	33
1.8.1 Chemical structure	33
1.8.2 Pharmacological action	34
1.8.3 Physiological classification	34
1.8.4 Prodrugs	35
1.9 Questions	35

2	Drug structure and solubility	37
2.1	Introduction	37
2.2	Structure	37
2.3	Stereochemistry and drug design	38
2.3.1	Structurally rigid groups	38
2.3.2	Conformation	39
2.3.3	Configuration	41
2.4	Solubility	44
2.4.1	Solubility and the physical nature of the solute	44
2.5	Solutions	46
2.6	The importance of water solubility	47
2.7	Solubility and the structure of the solute	49
2.8	Salt formation	50
2.9	The incorporation of water solubilising groups in a structure	52
2.9.1	The type of group	52
2.9.2	Reversible and irreversible groups	53
2.9.3	The position of the water solubilising group	53
2.9.4	Methods of introduction	54
2.9.5	Improving lipid solubility	59
2.10	Formulation methods of improving water solubility	59
2.10.1	Cosolvents	59
2.10.2	Colloidal solutions	59
2.10.3	Emulsions	60
2.11	The effect of pH on the solubility of acidic and basic drugs	61
2.12	Partition	63
2.12.1	Practical determination of partition coefficients	65
2.12.2	Theoretical determination of partition coefficients	66
2.13	Surfactants and amphiphiles	66
2.13.1	Drug solubilisation	69
2.13.2	Mixed micelles as drug delivery systems	71
2.13.3	Vesicles and liposomes	72
2.14	Questions	72
3	Structure–activity and quantitative structure relationships	75
3.1	Introduction	75
3.2	Structure–activity relationship (SAR)	76
3.3	Changing size and shape	77
3.3.1	Changing the number of methylene groups in chains and rings	77
3.3.2	Changing the degree of unsaturation	78
3.3.3	Introduction or removal of a ring system	78
3.4	Introduction of new substituents	80
3.4.1	Methyl groups	81
3.4.2	Halogen groups	83
3.4.3	Hydroxy groups	84
3.4.4	Basic groups	84
3.4.5	Carboxylic and sulphonic acid groups	85
3.4.6	Thiols, sulphides and other sulphur groups	85
3.5	Changing the existing substituents of a lead	86
3.6	Case study: a SAR investigation to discover potent geminal bisphosphonates	87
3.7	Quantitative structure–activity relationship (QSAR)	90
3.7.1	Regression analysis	93
3.7.2	The lipophilic parameters	94

3.7.3	Electronic parameters	99
3.7.4	Steric parameters	102
3.8	Questions	110
4	Computer-aided drug design	113
4.1	Introduction	113
4.1.1	Models	114
4.1.2	Molecular modelling methods	115
4.1.3	Computer graphics	116
4.2	Molecular mechanics	117
4.2.1	Creating a molecular model using molecular mechanics	120
4.3	Molecular dynamics	123
4.3.1	Conformational analysis	124
4.4	Quantum mechanics	124
4.5	Docking	127
4.5.1	<i>De novo</i> design	128
4.6	Comparing three-dimensional structures by the use of overlays	130
4.6.1	An example of the use of overlays	132
4.7	Pharmacophores and some of their uses	133
4.7.1	High-resolution X-ray crystallography or NMR	133
4.7.2	Analysis of the structures of different ligands	134
4.8	Modelling protein structures	135
4.9	Three-dimensional QSAR	136
4.9.1	Advantages and disadvantages	140
4.10	Other uses of computers in drug discovery	141
4.11	Questions	143
5	Combinatorial chemistry	145
5.1	Introduction	145
5.1.1	The design of combinatorial syntheses	147
5.1.2	The general techniques used in combinatorial synthesis	148
5.2	The solid support method	148
5.2.1	General methods in solid support combinatorial chemistry	150
5.2.2	Parallel synthesis	152
5.2.3	Furka's mix and split technique	155
5.3	Encoding methods	157
5.3.1	Sequential chemical tagging	157
5.3.2	Still's binary code tag system	160
5.3.3	Computerised tagging	161
5.4	Combinatorial synthesis in solution	161
5.4.1	Parallel synthesis in solution	162
5.4.2	The formation of libraries of mixtures	163
5.4.3	Libraries formed using monomethyl polyethylene glycol (OMe-PEG)	164
5.4.4	Libraries produced using dendrimers as soluble supports	164
5.4.5	Libraries formed using fluorocarbon reagents	165
5.4.6	Libraries produced using resin-bound scavenging agents	166
5.4.7	Libraries produced using resin-bound reagents	168
5.4.8	Resin capture of products	168
5.5	Deconvolution	169
5.6	High-throughput screening (HTS)	170
5.6.1	Biochemical assays	171
5.6.2	Whole cell assays	173
5.6.3	Hits and hit rates	173

5.7	Automatic methods of library generation and analysis	174
5.8	Questions	175
6	Drugs from natural sources	177
6.1	Introduction	177
6.2	Bioassays	179
6.2.1	Screening tests	180
6.2.2	Monitoring tests	183
6.3	Dereplication	185
6.4	Structural analysis of the isolated substance	186
6.5	Active compound development	188
6.6	Extraction procedures	189
6.6.1	General considerations	190
6.6.2	Commonly used methods of extraction	191
6.6.3	Cleaning up procedures	195
6.7	Fractionation methods	195
6.7.1	Liquid–liquid partition	196
6.7.2	Chromatographic methods	199
6.7.3	Precipitation	200
6.7.4	Distillation	200
6.7.5	Dialysis	202
6.7.6	Electrophoresis	202
6.8	Case history: the story of Taxol	202
6.9	Questions	206
7	Biological membranes	207
7.1	Introduction	207
7.2	The plasma membrane	208
7.2.1	Lipid components	209
7.2.2	Protein components	211
7.2.3	The carbohydrate component	213
7.2.4	Similarities and differences between plasma membranes in different cells	213
7.2.5	Cell walls	214
7.2.6	Bacterial cell exterior surfaces	217
7.2.7	Animal cell exterior surfaces	218
7.2.8	Virus	218
7.2.9	Tissue	219
7.2.10	Human skin	219
7.3	The transfer of species through cell membranes	220
7.3.1	Osmosis	220
7.3.2	Filtration	221
7.3.3	Passive diffusion	221
7.3.4	Facilitated diffusion	223
7.3.5	Active transport	223
7.3.6	Endocytosis	224
7.3.7	Exocytosis	225
7.4	Drug action that affects the structure of cell membranes and walls	225
7.4.1	Antifungal agents	226
7.4.2	Antibacterial agents (antibiotics)	230
7.4.3	Local anaesthetics	244
7.5	Questions	249

8	Receptors and messengers	251
8.1	Introduction	251
8.2	The chemical nature of the binding of ligands to receptors	252
8.3	Structure and classification of receptors	254
8.4	General mode of operation	256
8.4.1	Superfamily Type 1	259
8.4.2	Superfamily Type 2	260
8.4.3	Superfamily Type 3	263
8.4.4	Superfamily Type 4	264
8.5	Ligand–response relationships	265
8.5.1	Experimental determination of ligand concentration–response curves	266
8.5.2	Agonist concentration–response relationships	267
8.5.3	Antagonist concentration–receptor relationships	268
8.5.4	Partial agonists	271
8.5.5	Desensitisation	272
8.6	Ligand–receptor theories	272
8.6.1	Clark’s occupancy theory	272
8.6.2	The rate theory	277
8.6.3	The two-state model	278
8.7	Drug action and design	279
8.7.1	Agonists	279
8.7.2	Antagonists	281
8.7.3	Citalopram, an antagonist antidepressant discovered by a rational approach	282
8.7.4	β -Blockers	285
8.8	Questions	289
9	Enzymes	291
9.1	Introduction	291
9.2	Classification and nomenclature	293
9.3	Active sites and catalytic action	295
9.3.1	Allosteric activation	297
9.4	Regulation of enzyme activity	298
9.4.1	Covalent modification	298
9.4.2	Allosteric control	298
9.4.3	Proenzyme control	300
9.5	The specific nature of enzyme action	300
9.6	The mechanisms of enzyme action	302
9.7	The general physical factors affecting enzyme action	302
9.8	Enzyme kinetics	303
9.8.1	Single substrate reactions	303
9.8.2	Multiple substrate reactions	305
9.9	Enzyme inhibitors	306
9.9.1	Reversible inhibitors	307
9.9.2	Irreversible inhibition	312
9.10	Transition state inhibitors	318
9.11	Enzymes and drug design: some general considerations	320
9.12	Examples of drugs used as enzyme inhibitors	321
9.12.1	Sulphonamides	321
9.12.2	Captopril and related drugs	323
9.12.3	Statins	326
9.13	Enzymes and drug resistance	329
9.13.1	Changes in enzyme concentration	330

9.13.2	An increase in the production of the substrate	331
9.13.3	Changes in the structure of the enzyme	331
9.13.4	The use of an alternative metabolic pathway	332
9.14	Ribozymes	332
9.15	Questions	332
10	Nucleic acids	335
10.1	Introduction	335
10.2	Deoxyribonucleic acid (DNA)	336
10.2.1	Structure	337
10.3	The general functions of DNA	338
10.4	Genes	339
10.5	Replication	340
10.6	Ribonucleic acid (RNA)	341
10.7	Messenger RNA (mRNA)	342
10.8	Transfer RNA (tRNA)	343
10.9	Ribosomal RNA (rRNA)	345
10.10	Protein synthesis	345
10.10.1	Activation	345
10.10.2	Initiation	346
10.10.3	Elongation	347
10.10.4	Termination	348
10.11	Protein synthesis in prokaryotic and eukaryotic cells	348
10.11.1	Prokaryotic cells	348
10.11.2	Eukaryotic cells	350
10.12	Bacterial protein synthesis inhibitors (antimicrobials)	350
10.12.1	Aminoglycosides	351
10.12.2	Chloramphenicol	355
10.12.3	Tetracyclines	356
10.12.4	Macrolides	359
10.12.5	Lincomycins	360
10.13	Drugs that target nucleic acids	362
10.13.1	Antimetabolites	362
10.13.2	Enzyme inhibitors	368
10.13.3	Intercalating agents	372
10.13.4	Alkylating agents	374
10.13.5	Antisense drugs	377
10.13.6	Chain cleaving agents	379
10.14	Viruses	380
10.14.1	Structure and replication	380
10.14.2	Classification	381
10.14.3	Viral diseases	383
10.14.4	Antiviral drugs	384
10.15	Recombinant DNA technology (genetic engineering)	389
10.15.1	Gene cloning	389
10.15.2	Medical applications	392
10.16	Questions	401
11	Pharmacokinetics	403
11.1	Introduction	403
11.1.1	General classification of pharmacokinetic properties	405
11.1.2	Drug regimens	405
11.1.3	The importance of pharmacokinetics in drug discovery	406
11.2	Drug concentration analysis and its therapeutic significance	407

11.3	Pharmacokinetic models	409
11.4	Intravascular administration	411
11.4.1	Distribution	412
11.5	Extravascular administration	425
11.5.1	Dissolution	428
11.5.2	Absorption	429
11.5.3	Single oral dose	430
11.5.4	The calculation of t_{\max} and C_{\max}	433
11.5.5	Repeated oral doses	434
11.6	The use of pharmacokinetics in drug design	435
11.7	Extrapolation of animal experiments to humans	435
11.8	Questions	436
12	Drug metabolism	439
12.1	Introduction	439
12.1.1	The stereochemistry of drug metabolism	439
12.1.2	Biological factors affecting metabolism	440
12.1.3	Environmental factors affecting metabolism	443
12.1.4	Species and metabolism	443
12.1.5	Enzymes and metabolism	443
12.2	Secondary pharmacological implications of metabolism	443
12.2.1	Inactive metabolites	444
12.2.2	Metabolites with a similar activity to the drug	444
12.2.3	Metabolites with a dissimilar activity to the drug	444
12.2.4	Toxic metabolites	445
12.3	Sites of action	445
12.4	Phase I metabolic reactions	446
12.4.1	Oxidation	446
12.4.2	Reduction	448
12.4.3	Hydrolysis	448
12.4.4	Hydration	449
12.4.5	Other Phase I reactions	449
12.5	Examples of Phase I metabolic reactions	449
12.6	Phase II metabolic routes	454
12.7	Pharmacokinetics of metabolites	457
12.8	Drug metabolism and drug design	458
12.9	Prodrugs	460
12.9.1	Bioprecursor prodrugs	461
12.9.2	Carrier prodrugs	462
12.9.3	Photoactivated prodrugs	464
12.9.4	The design of carrier prodrug systems for specific purposes	465
12.10	Questions	475
13	Complexes and chelating agents	477
13.1	Introduction	477
13.2	The shapes and structures of complexes	478
13.2.1	Ligands	479
13.2.2	Bridging ligands	483
13.2.3	Metal-metal bonds	483
13.2.4	Metal clusters	483
13.3	Metal-ligand affinities	485
13.3.1	Affinity and equilibrium constants	485
13.3.2	Hard and soft acids and bases	487

13.3.3	The general medical significance of complex stability	488
13.4	The general roles of metal complexes in biological processes	488
13.5	Therapeutic uses	491
13.5.1	Metal poisoning	491
13.5.2	Anticancer agents	494
13.5.3	Antiarthritics	497
13.5.4	Antimicrobial complexes	498
13.5.5	Photoactivated metal complexes	499
13.6	Drug action and metal chelation	501
13.7	Questions	501
14	Nitric oxide	503
14.1	Introduction	503
14.2	The structure of nitric oxide	503
14.3	The chemical properties of nitric oxide	504
14.3.1	Oxidation	505
14.3.2	Salt formation	506
14.3.3	Reaction as an electrophile	507
14.3.4	Reaction as an oxidising agent	507
14.3.5	Complex formation	508
14.3.6	Nitric oxide complexes with iron	508
14.3.7	The chemical properties of nitric oxide complexes	510
14.3.8	The chemistry of related compounds	512
14.4	The cellular production and role of nitric oxide	514
14.4.1	General mode of action	516
14.4.2	Suitability of nitric oxide as a chemical messenger	518
14.4.3	Metabolism	518
14.5	The role of nitric oxide in physiological and pathophysiological states	519
14.5.1	The role of nitric oxide in the cardiovascular system	519
14.5.2	The role of nitric oxide in the nervous system	520
14.5.3	Nitric oxide and diabetes	522
14.5.4	Nitric oxide and impotence	522
14.5.5	Nitric oxide and the immune system	523
14.6	Therapeutic possibilities	524
14.6.1	Compounds that reduce nitric oxide generation	524
14.6.2	Compounds that supply nitric oxide	526
14.6.3	The genetic approach	529
14.7	Questions	529
15	An introduction to drug and analogue synthesis	531
15.1	Introduction	531
15.2	Some general considerations	532
15.2.1	Starting materials	532
15.2.2	Practical considerations	532
15.2.3	The overall design	532
15.2.4	The use of protecting groups	533
15.3	Asymmetry in syntheses	534
15.3.1	The use of non-stereoselective reactions to produce stereospecific centres	535
15.3.2	The use of stereoselective reactions to produce stereogenetic centres	535
15.3.3	General methods of asymmetric synthesis	541
15.3.4	Methods of assessing the purity of stereoisomers	547
15.4	Designing organic syntheses	548
15.4.1	An introduction to the disconnection approach	548

15.4.2	Convergent synthesis	554
15.5	Partial organic synthesis of xenobiotics	556
15.6	Questions	557
16	Drug development and production	559
16.1	Introduction	559
16.2	Chemical development	560
16.2.1	Chemical engineering issues	561
16.2.2	Chemical plant: health and safety considerations	562
16.2.3	Synthesis quality control	563
16.2.4	A case study	563
16.3	Pharmacological and toxicological testing	565
16.4	Drug metabolism and pharmacokinetics	569
16.5	Formulation development	570
16.6	Production and quality control	570
16.7	Patent protection	571
16.8	Regulation	572
16.9	Questions	573
	Selected further reading	575
	Answers to questions	579
	Index	601

